C Vlachopoulos
Overview
Explore the profile of C Vlachopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katsiki N, Filippatos T, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A, et al.
Atheroscler Plus
. 2024 Mar;
55:74-92.
PMID: 38425675
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor...
2.
Vlachopoulos C, Massia D, Kochiadakis G, Kolovou G, Patsilinakos S, Bridges I, et al.
Hellenic J Cardiol
. 2023 Sep;
74:74-76.
PMID: 37730147
No abstract available.
3.
Oikonomou E, Aznaouridis K, Barbetseas J, Charalambous G, Gastouniotis I, Fotopoulos V, et al.
Public Health
. 2020 Sep;
187:115-119.
PMID: 32949881
Objectives: The coronavirus disease 2019 (COVID-19) outbreak, along with implementation of lockdown and strict public movement restrictions, in Greece has affected hospital visits and admissions. We aimed to investigate trends...
4.
Sanz M, Del Castillo A, Jepsen S, Gonzalez-Juanatey J, DAiuto F, Bouchard P, et al.
Glob Heart
. 2020 Jun;
15(1):1.
PMID: 32489774
Background: In Europe cardiovascular disease (CVD) is responsible for 3.9 million deaths (45% of deaths), being ischaemic heart disease, stroke, hypertension (leading to heart failure) the major cause of these...
5.
Visvikis A, Kyvelou S, Pietri P, Georgakopoulos C, Manousou K, Tousoulis D, et al.
Cancer Manag Res
. 2020 Feb;
12:1175-1185.
PMID: 32104097
Background And Purpose: Even though new cancer therapies have improved the overall survival, in some cases they have been associated with adverse effects, including increased cardiotoxicity. The purpose of the...
6.
Vlachopoulos C, Andrikopoulos G, Terentes-Printzios D, Tzeis S, Iliodromitis E, Richter D, et al.
Curr Vasc Pharmacol
. 2017 Jul;
16(4):405-413.
PMID: 28676022
Background: Current European Guidelines suggest the use of cardiovascular risk categories and also recommend using high-intensity statins for patients with acute coronary syndromes (ACS). Objective: We examined the risk of...
7.
Vlachopoulos C, Gravos A, Georgiopoulos G, Terentes-Printzios D, Ioakeimidis N, Vassilopoulos D, et al.
Clin Rheumatol
. 2017 May;
37(2):515-526.
PMID: 28484887
Patients with rheumatoid arthritis (RA) have higher aortic stiffness and cardiovascular risk. Tumor necrosis factor alpha (TNF-a) antagonists reduce inflammation in RA and are indicated for the treatment of patients...
8.
Andrikopoulos G, Terentes-Printzios D, Tzeis S, Vlachopoulos C, Varounis C, Nikas N, et al.
Hellenic J Cardiol
. 2016 Jul;
57(3):157-166.
PMID: 27451914
Introduction: In view of recent therapeutic breakthroughs in acute coronary syndromes (ACS) and essential demographic and socioeconomic changes in Greece, we conducted the prospective, multi-center, nationwide PHAETHON study (An Epidemiological...
9.
Vlachopoulos C, Grammatikou V, Kallistratos M, Karagiannis A
Curr Med Res Opin
. 2016 May;
32(9):1605-10.
PMID: 27209900
Objective: The rates of blood pressure (BP) control worldwide are discouraging. This study had the purpose of assessing the effectiveness of perindopril/amlodipine fixed dose combination on BP-lowering efficacy, and recording...
10.
Lazaros G, Vasileiou P, Danias P, Koutsianas C, Vlachopoulos C, Tousoulis D, et al.
Clin Exp Rheumatol
. 2015 Oct;
33(6):945.
PMID: 26516795
No abstract available.